Description:
Avelumab in combination with talazoparib will be investigated in patients with locally
advanced (primary or recurrent) or metastatic solid tumors, including non-small cell lung
cancer (NSCLC), triple negative breast cancer (TNBC), hormone receptor positive (HR+) breast
cancer, recurrent platinum sensitive ovarian cancer, urothelial cancer (UC), and castration
resistant prostate cancer (CRPC).
Title
- Brief Title: Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors
- Official Title: A PHASE 1B/2 STUDY TO EVALUATE SAFETY AND ANTI TUMOR ACTIVITY OF AVELUMAB IN COMBINATION WITH THE POLY(ADENOSINE DIPHOSPHATE [ADP]-RIBOSE) POLYMERASE (PARP) INHIBITOR TALAZOPARIB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS
Clinical Trial IDs
- ORG STUDY ID:
B9991025
- SECONDARY ID:
2017-001509-33
- SECONDARY ID:
JAVELIN PARP MEDLEY
- NCT ID:
NCT03330405
Conditions
- Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors
Interventions
Drug | Synonyms | Arms |
---|
Avelumab Phase 1b | MSB0010718C | Dose Level -1 Phase 1b |
Talazoparib Phase 1b | MDV3800, BMN 673 | Dose Level -1 Phase 1b |
Avelumab Phase 2 | MSB0010718C | A1. NSCLC Phase 2 |
Talazoparib Phase 2 | MDV3800, BMN 673 | A1. NSCLC Phase 2 |
Purpose
Avelumab in combination with talazoparib will be investigated in patients with locally
advanced (primary or recurrent) or metastatic solid tumors, including non-small cell lung
cancer (NSCLC), triple negative breast cancer (TNBC), hormone receptor positive (HR+) breast
cancer, recurrent platinum sensitive ovarian cancer, urothelial cancer (UC), and castration
resistant prostate cancer (CRPC).
Detailed Description
Avelumab is a human immunoglobulin (Ig)G1 monoclonal antibody (mAb) directed against
programmed death ligand 1 (PD L1). Avelumab selectively binds to PD L1 and competitively
blocks its interaction with programmed death receptor 1 (PD 1), thereby interfering with this
key immune checkpoint inhibition pathway. Avelumab is currently being investigated as single
agent and in combination with other anti cancer therapies in patients with locally advanced
or metastatic solid tumors and various hematological malignancies.
Talazoparib is a potent, orally bioavailable poly (adenosine diphosphate [ADP] ribose)
polymerase (PARP) inhibitor, which is cytotoxic to human cancer cell lines harboring gene
mutations that compromise deoxyribonucleic acid (DNA) repair, an effect referred to as
synthetic lethality, and by trapping PARP protein on DNA thereby preventing DNA repair,
replication, and transcription.
Avelumab in combination with talazoparib will be investigated in patients with locally
advanced (primary or recurrent) or metastatic solid tumors, including non-small cell lung
cancer (NSCLC), triple negative breast cancer (TNBC), hormone receptor positive (HR+) breast
cancer, recurrent platinum sensitive ovarian cancer, urothelial cancer (UC), and castration
resistant prostate cancer (CRPC).
Trial Arms
Name | Type | Description | Interventions |
---|
Dose Level 0 Phase 1b | Experimental | Drug: Avelumab
Drug: Talazoparib | - Avelumab Phase 1b
- Talazoparib Phase 1b
|
Dose Level -1 Phase 1b | Experimental | Drug: Avelumab
Drug: Talazoparib | - Avelumab Phase 1b
- Talazoparib Phase 1b
|
Dose Level -2 Phase 1b | Experimental | Drug: Avelumab
Drug: Talazoparib | - Avelumab Phase 1b
- Talazoparib Phase 1b
|
A1. NSCLC Phase 2 | Experimental | Drug: Avelumab
Drug: Talazoparib | - Avelumab Phase 2
- Talazoparib Phase 2
|
A2. NSCLC PD-L1 Resistant DDR+ Phase 2 | Experimental | Drug: Avelumab
Drug: Talazoparib | - Avelumab Phase 2
- Talazoparib Phase 2
|
B1. TNBC Phase 2 | Experimental | Drug: Avelumab
Drug: Talazoparib | - Avelumab Phase 2
- Talazoparib Phase 2
|
B2. HR+BC DDR Defect +Assay Phase 2 | Experimental | Drug: Avelumab
Drug: Talazoparib | - Avelumab Phase 2
- Talazoparib Phase 2
|
C1. Ovarian CA Recurrent Plat-Sensitive Phase 2 | Experimental | Drug: Avelumab
Drug: Talazoparib | - Avelumab Phase 2
- Talazoparib Phase 2
|
C2.Ovarian CA Recurrent Plat-Sensitive BRCA defect Phase 2 | Experimental | Drug: Avelumab
Drug: Talazoparib | - Avelumab Phase 2
- Talazoparib Phase 2
|
D.Urothelial CA Phase 2 | Experimental | Drug: Avelumab
Drug: Talazoparib | - Avelumab Phase 2
- Talazoparib Phase 2
|
E1. CRPC Phase 2 | Experimental | Drug: Avelumab
Drug: Talazoparib | - Avelumab Phase 2
- Talazoparib Phase 2
|
E2. CRPC DDR Defect +Assay Phase 2 | Experimental | Drug: Avelumab
Drug: Talazoparib | - Avelumab Phase 2
- Talazoparib Phase 2
|
F: Advanced Solid Tumors with BRCA or ATM defect Phase 2 | Experimental | Drug: Avelumab
Drug: Talazoparib | - Avelumab Phase 2
- Talazoparib Phase 2
|
Eligibility Criteria
Inclusion Criteria:
- Histological diagnosis of locally advanced (primary or recurrent) or metastatic solid
tumors that are not amenable for treatment with curative intent in adult patients
with: NSCLC, TNBC, HR+ breast cancer, recurrent platinum sensitive ovarian cancer, UC,
CRPC, and other advanced solid tumors with a BRCA or ATM gene defect
- Mandatory primary or metastatic tumor biopsy. If archival tumor tissue is available
from a biopsy/surgery the tumor tissue may be submitted without repeating a tumor
biopsy during the screening period.
- Minimum age in Japan is 20 years.
- ECOG performance status 0 or 1.
- Resolved acute effects of prior therapy
- Adequate bone marrow, renal, and liver function.
- Negative serum pregnancy test at screening.
- Pregnant, breastfeeding females or female patients able to have children must agree to
use highly effective method of contraception throughout the study and for at least 30
days after the last dose of avelumab and for at least 7 months after the last dose of
talazoparib; fertile male patients must use a condom during treatment and for at least
4 months after the last dose of talazoparib.
- Signed and dated informed consent.
Exclusion Criteria:
- Prior treatment with a PARP inhibitor.
- Prior immunotherapy with IL-2, IFN-α, or an anti-PD-1, anti-PD-L1, anti-PD-L2,
anti-CD137, OX 40, GITR, LAG 3, IDO, TDO,TIM 3, CTLA-4 antibody, or any other antibody
or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways.
Prior treatment with Sipuleucel-T for patients with mCRPC is allowed. For cohort A2
NSCLC patients prior treatment with anti-PD-1/L1 is allowed
- Prior anti-cancer therapy within 2 weeks prior to study enrollment. Prior radiation
therapy within 2 weeks prior to enrollment. Prior palliative radiotherapy to
metastatic lesion(s) is permitted, provided it has been completed 2 days prior to
study enrollment and no clinically significant toxicities are expected (eg, mucositis,
esophagitis).
- Major surgery within 4 weeks prior to study enrollment.
- Current use of immunosuppressive medication at the time of study enrollment.
- Known prior or suspected hypersensitivity to investigational products.
- Known history of immune mediated colitis, inflammatory bowel disease, pneumonitis,
pulmonary fibrosis.
- Active or prior autoimmune disease that might deteriorate when receiving an
immunostimulatory agent.
- Prior organ transplantation including allogenic stem-cell transplantation.
- Vaccination within 4 weeks of study enrollment and while on trial is prohibited except
for administration of inactivated vaccines.
- Diagnosis of Myelodysplastic Syndrome.
- Patients with known brain metastases requiring steroids.
- Participation in other studies involving investigational drug(s) within 4 weeks prior
to study participation and/or during study participation.
- Persisting toxicity related to prior therapy >Grade 1
- Known HIV or AIDs-related illness.
- Positive HBV or HCV test indicating acute or chronic infection.
- Active infection requiring systemic therapy.
- Clinically significant cardiovascular disease: cerebral vascular accident/stroke or
myocardial infarction within 6 months prior to study entry; unstable angina,
congestive heart failure or a serious cardiac arrhythmia requiring medication.
- Current or anticipated use within 7 days prior to first dose of study drug, or
anticipated use during the study of a strong P-gp inhibitor.
- Other acute or chronic medical or psychiatric conditions.
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Dose Limiting Toxicity (DLT) |
Time Frame: | Cycle 1 Days 1-28 (28 days from date of first dose of study treatment) |
Safety Issue: | |
Description: | Phase 1b: DLT during the DLT evaluation period (Cycle 1) |
Secondary Outcome Measures
Measure: | Serum concentrations of avelumab |
Time Frame: | Day 1 Cycles 1-4, 6, 9, 12, 18, 24 and Day 15 Cycle 1 |
Safety Issue: | |
Description: | Pharmacokinetic parameters: pre-dose/trough concentrations (Ctrough) |
Measure: | Anti drug antibody (ADA) levels of avelumab |
Time Frame: | Day 1 Cycles 1-4, 6,9,12,18, 24 and Day 15 Cycle 1 |
Safety Issue: | |
Description: | Immunogenicity assessment of avelumab |
Measure: | OR |
Time Frame: | From the start of treatment until disease progression/recurrence up to approximately 24 months |
Safety Issue: | |
Description: | Phase 1b: Confirmed OR, as assessed by the Investigator using RECIST v1.1 in patients with locally advanced or metastatic solid tumors and RECIST v1.1 and PCWG3 in patients with metastatic CRPC. |
Measure: | PSA Tumor Marker |
Time Frame: | Baseline, Day1 of each cycle (each cycle is 28 days), and End of Treatment ( up to approximately 24 months) |
Safety Issue: | |
Description: | PSA response greater than or equal to 50% for patients with metastatic CRPC. |
Measure: | CA-125 Tumor Marker |
Time Frame: | Baseline, Day1 of each cycle (each cycle is 28 days), and End of Treatment (up to approximately 24 months) |
Safety Issue: | |
Description: | CA-125 response for patients with ovarian cancer. |
Measure: | Biomarker PD-L1 |
Time Frame: | Baseline |
Safety Issue: | |
Description: | PD-L1 expression level in baseline tumor tissue. |
Measure: | Genomic |
Time Frame: | Baseline |
Safety Issue: | |
Description: | Genomic scarring and the presence of defects in select genes, considered critical to effective DDR, in baseline tumor tissue. |
Measure: | Serum concentrations of avelumab |
Time Frame: | Day 1 Cycles 1-4, 6,9,12,18, 24 and Day 15 Cycle 1 |
Safety Issue: | |
Description: | Pharmacokinetic parameters: maximum concentrations (Cmax) |
Measure: | Plasma concentrations of talazoparib |
Time Frame: | Day 1 Cycles 1-4 and Day 15 Cycle 1 |
Safety Issue: | |
Description: | Pharmacokinetic parameters: pre-dose/trough concentrations (Ctrough) |
Measure: | Plasma concentration of talazoparib |
Time Frame: | Day 1 Cycles 1-4 and Day 15 Cycle 1 |
Safety Issue: | |
Description: | Pharmacokinetic parameters: post-dose concentrations |
Measure: | Neutralizing antibodies (Nab) levels against avelumab. |
Time Frame: | Day 1 Cycles 1-4, 6, 9, 12, 18, 24 and Day 15 Cycle 1 |
Safety Issue: | |
Description: | Immunogenicity assessment of avelumab |
Measure: | Time to Tumor Response (TTR) |
Time Frame: | Baseline up to approximately 24 months |
Safety Issue: | |
Description: | Time to Tumor Response (TTR) is defined for patients with confirmed objective response (CR or PR) as the time from the first dose of study treatment to the first documentation of objective tumor response. |
Measure: | Duration of response (DR) |
Time Frame: | Baseline up to approximately 24 months |
Safety Issue: | |
Description: | Duration of Response (DR) is defined for patients with confirmed objective response (complete response [CR] or partial response [PR]) as the time from the first documentation of objective tumor response to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first. |
Measure: | Progression-Free Survival (PFS) |
Time Frame: | Baseline up to approximately 24 months |
Safety Issue: | |
Description: | Progression Free Survival (PFS) is defined as the time from the first dose of study treatment to the date of disease progression by RECIST v1.1 or death due to any cause, whichever occurs first. |
Measure: | Prostate-Specific Antigen (PSA) response |
Time Frame: | Baseline up to approximately 24 months |
Safety Issue: | |
Description: | PSA response is defined as the proportion of patients with confirmed PSA decline greater than or equal to 50% compared to baseline. |
Measure: | Overall Survival (OS) |
Time Frame: | Baseline up to approximately 24 months |
Safety Issue: | |
Description: | OS is defined as the time from the first dose of study treatment to the date of death. |
Measure: | Biomarker Tumor Mutational Burden |
Time Frame: | Baseline |
Safety Issue: | |
Description: | Tumor mutational burden in baseline tumor tissue |
Details
Phase: | Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Active, not recruiting |
Lead Sponsor: | Pfizer |
Trial Keywords
- NSCLC, TNBC, hormone receptor positive (HR+) breast cancer, recurrent epithelial ovarian cancer, UC, and castration resistant prostate cancer (CRPC).
Last Updated
January 20, 2021